OGN (Organon) Total Operating Expense: $2,088 Mil (TTM As of Mar. 2026)


OGN Organon & Co OGN
71 GF Score
Price $13.50
GF Value $14.55
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Organon Total Operating Expense?

Organon OGN +0.22% 71 Total Operating Expense is $2,088 Mil as of Mar. 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 10 warning signs investors should review.

Organon's Total Operating Expense for the three months ended in Mar. 2026 was $517 Mil. Organon's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $2,088 Mil.

Organon Total Operating Expense Related Terms

Organon Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Organon's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon Total Operating Expense Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 2,007.00 2,175.00 2,421.00 2,229.00 2,087.00

Organon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 516.00 548.00 499.00 524.00 517.00
OGN
71GF Score
Organon & Co OGN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organon Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,088 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $2,088 Mil mean?
Organon (OGN) has a Total Operating Expense of $2,088 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Organon and its competitors.
Is Organon's Total Operating Expense too high?
Organon's current Total Operating Expense is $2,088 Mil. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Total Operating Expense compare to AMRN and SCLX?
Organon's Total Operating Expense of $2,088 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Organon and its competitors. Organon's current Total Operating Expense is $2,088 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.50 — trading 7.2% below its estimated fair value. The current Total Operating Expense is $2,088 Mil. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Organon (OGN), the current Total Operating Expense is $2,088 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.50 is trading 7.2% below its estimated GF Value™ of $14.55. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Total Operating Expense: $2,088 Mil
  • GF Value™: $14.55 vs. price of $13.50 (7.2% below fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.50
Price
$14.55
GF Value